



OPEN ACCESS

ORIGINAL RESEARCH

# Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic *TP53* mutation carriers: a case-controlled study (SIGNIFY)

Elizabeth K Bancroft ,<sup>1,2</sup> Sibel Saya ,<sup>2,3</sup> Emma Brown,<sup>4</sup> Sarah Thomas,<sup>1</sup> Natalie Taylor,<sup>1</sup> Jeanette Rothwell,<sup>5</sup> Jennifer Pope,<sup>2</sup> Anthony Chamberlain,<sup>2</sup> Elizabeth Page,<sup>2</sup> Sarah Benafif,<sup>2</sup> Helen Hanson,<sup>6</sup> Alexander Dias,<sup>2</sup> Christos Mikropoulos,<sup>7</sup> Louise Izatt,<sup>8</sup> Lucy Side,<sup>9</sup> Lisa Walker,<sup>10</sup> Alan Donaldson,<sup>11</sup> Jackie A Cook,<sup>12</sup> Julian Barwell,<sup>13</sup> Vicki Wiles,<sup>14</sup> Lauren Limb,<sup>15</sup> Diana M Eccles ,<sup>16</sup> Martin O Leach,<sup>17,18</sup> Susan Shanley,<sup>19</sup> Fiona J Gilbert,<sup>20</sup> David Gallagher,<sup>21</sup> Balashanmugam Rajashanker,<sup>22,23</sup> Richard W Whitehouse,<sup>22</sup> Dow-Mu Koh,<sup>17,18</sup> S Aslam Sohaib,<sup>17</sup> D Gareth Evans ,<sup>5</sup> Rosalind A Eeles,<sup>1,2</sup> Leslie G Walker<sup>24</sup>

For numbered affiliations see end of article.

## Correspondence to

Dr Elizabeth K Bancroft, Royal Marsden NHS Foundation Trust, London, UK; [elizabeth.bancroft@rmh.nhs.uk](mailto:elizabeth.bancroft@rmh.nhs.uk)

Received 27 June 2019  
Revised 18 September 2019  
Accepted 21 September 2019  
Published Online First 12 November 2019

## ABSTRACT

**Background** Germline *TP53* gene pathogenic variants (pv) cause a very high lifetime risk of developing cancer, almost 100% for women and 75% for men. In the UK, annual MRI breast screening is recommended for female *TP53* pv carriers. The SIGNIFY study (Magnetic Resonance Imaging screening in Li Fraumeni syndrome: An exploratory whole body MRI) study reported outcomes of whole-body MRI (WB-MRI) in a cohort of 44 *TP53* pv carriers and 44 matched population controls. The results supported the use of a baseline WB-MRI screen in all adult *TP53* pv carriers. Here we report the acceptability of WB-MRI screening and effects on psychosocial functioning and health-related quality of life in the short and medium terms.

**Methods** Psychosocial and other assessments were carried out at study enrolment, immediately before MRI, before and after MRI results, and at 12, 26 and 52 weeks' follow-up.

**Results** WB-MRI was found to be acceptable with high levels of satisfaction and low levels of psychological morbidity throughout. Although their mean levels of cancer worry were not high, carriers had significantly more cancer worry at most time-points than controls. They also reported significantly more clinically significant intrusive and avoidant thoughts about cancer than controls at all time-points. There were no clinically significant adverse psychosocial outcomes in either carriers with a history of cancer or in those requiring further investigations.

**Conclusion** WB-MRI screening can be implemented in *TP53* pv carriers without adverse psychosocial outcomes in the short and medium terms. A previous cancer diagnosis may predict a better psychosocial outcome. Some carriers seriously underestimate their risk of cancer. Carriers of pv should have access to a clinician to help them develop adaptive strategies to cope with cancer-related concerns and respond to clinically significant depression and/or anxiety.

## INTRODUCTION

Li-Fraumeni syndrome (LFS) is a rare, dominantly inherited, highly penetrant cancer predisposition

syndrome. The majority of families have a germline pathogenic variant (pv) in the *TP53* gene.<sup>1–4</sup> The cancers associated with LFS include breast cancer, sarcoma, adrenocortical carcinoma and brain tumours.<sup>3,4</sup> Cancers are typically early onset (two to three decades before the median general population incidence) and there is also an increased risk of other cancers.<sup>5–7</sup> The lifetime risk of cancer is very high for pv carriers when detected in a clinical context: almost 100% for women and 75% for men.<sup>8</sup> However, our understanding of penetrance and cancer patterns is incomplete, as evidence from genome-wide studies has identified pv in *TP53* in individuals who do not meet the LFS testing criteria.<sup>8</sup>

In 2016, the American Association for Cancer Research held a meeting of international LFS experts to develop consensus cancer surveillance recommendations. A combination of physical exams, blood tests and imaging based on the earlier 'Toronto protocol' was proposed.<sup>9,10</sup> In the UK, current screening guidelines for *TP53* mutation carriers recommend annual MRI breast screening in women aged 20–49 and advise considering continuing this regimen past the age of 50.<sup>11,12</sup> Discussion of risk-reducing mastectomy is also recommended. Screening across UK genetics centres is variable, most offering a rapid review of symptoms in carriers.<sup>12</sup>

Internationally, there is increasing interest in the use of whole-body MRI (WB-MRI) as a screening tool,<sup>9–18</sup> because, unlike other imaging approaches, ionising radiation, which may further increase cancer risk, is not used. In the UK, the SIGNIFY (Magnetic Resonance Imaging screening in Li Fraumeni syndrome: An exploratory whole body MRI) study recently reported the outcomes of WB-MRI in a cohort of 44 *TP53* pv carriers and 44 matched population controls.<sup>12</sup> The results supported the use of a baseline WB-MRI screen as a minimum in all *TP53* pv carriers in addition to the established breast screening programme.<sup>12</sup> Further evidence supporting the use of a baseline WB-MRI screen for early detection of



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Bancroft EK, Saya S, Brown E, et al. *J Med Genet* 2020;**57**:226–236.

treatable tumours comes from a meta-analysis of 13 cohorts with a total of 578 *TP53* pv carriers.<sup>14</sup> An annual WB-MRI screen for all *TP53* pv carriers is being considered for adoption as a national guideline in the UK.<sup>18</sup>

Alongside clinical outcomes, it is important to evaluate possible psychosocial morbidity associated with screening. The psychosocial impact of screening with WB-MRI in *TP53* carriers is largely unknown. An Australian group evaluated the use of WB-MRI in a cohort of 17 *TP53* carriers. They found that participants were not overburdened and they experienced mainly positive psychological outcomes from participation.<sup>17</sup> However, this study reports only preliminary results from a small cohort and longer longitudinal studies are required.

A German group evaluated the psychosocial impact of WB-MRI in a healthy general population cohort. They found that participants overestimated the personal benefit of undergoing WB-MRI and experienced no long-term effects on health-related quality of life (HRQoL) or depressive symptoms.<sup>19</sup> However, those requiring further investigations for incidental findings experienced moderate or severe psychological distress.<sup>20</sup>

The UK MARIBS study (study of magnetic resonance imaging (MRI) for breast screening) evaluated annual breast MRI and mammography screening in *BRCA1/2* pv carriers at a significantly high risk for breast cancer.<sup>21 22</sup> Both imaging techniques were acceptable; psychological morbidity was low, and women were significantly less anxious and depressed after screening than they had been at baseline. However, MRI caused greater distress than mammograms, and this MRI-related distress was found to persist at 6 weeks' follow-up. The psychosocial impact of annual WB-MRI in *TP53* carriers requires further investigation.

Here we report the short-term and medium-term psychosocial effects, HRQoL and acceptability of WB-MRI scanning carried out as part of the SIGNIFY study.

## METHODS

### Study subjects and procedures

The SIGNIFY study compared the incidence of malignancies diagnosed in asymptomatic *TP53* pv carriers using WB-MRI screening with that in general population controls. It also assessed the incidence of non-malignant disease, the investigations required to determine the relevance of non-malignant disease, and the psychosocial impact and acceptability of WB-MRI screening. Full details of design, methods and results have been reported previously.<sup>12</sup>

Participants were recruited between November 2012 and July 2016 and consisted of two cohorts: *TP53* pv carriers, and age-matched ( $\pm 5$  years) and sex-matched population controls.

*TP53* pv carriers were identified and recruited consecutively through clinical genetics services in the UK and Ireland and referred to either the Royal Marsden NHS Foundation Trust (RMH) or the Central Manchester University Hospitals NHS Foundation Trust. Inclusion criteria were carriers of a germline *TP53* pv (not known to be low penetrance or a variant of unknown significance in the opinion of a geneticist) and aged between 18 and 60 years. Carriers with a malignancy diagnosed in the previous 5 years (except for non-melanomatous skin cancer or cervical carcinoma in situ) were excluded. Population controls were recruited in London through local advertisements and seen at the RMH. Inclusion criteria for controls were no personal history of cancer, no current symptoms suggestive of cancer and a minimal family history of cancer (no first-degree relative diagnosed <50 years, and at most only one first-degree, second-degree or third-degree relative diagnosed at any age).

All participants were invited to take part in this concurrent psychosocial study. The psychosocial impact was assessed using a set of standardised questionnaires adapted from those used in the MARIBS study.<sup>22</sup> The questionnaires measured anxiety and depression, cancer worry, physical and psychological health, perceived risk of cancer, satisfaction with the process of screening, and the presence of intrusive thoughts relating to MRI screening and cancer anxiety. Those participants with a previous cancer diagnosis but meeting the eligibility criteria were asked to answer in respect to their cancer worries relating to a future diagnosis.

Questionnaire booklets were administered at seven time-points: (1) study enrolment (baseline), (2) on arrival at the MRI appointment, (3) pre-MRI and (4) post-MRI results, and (5) 12, (6) 26 and (7) 52 weeks post results. Questionnaires 1–4 were administered for all patients entered into the study. Questionnaires 5–7 were administered only for patients not diagnosed with cancer during the course of the study, as a result of the WB-MRI. Those diagnosed with cancer during the course of the study were invited to complete the questionnaires, as appropriate, up to the time of diagnosis. Each questionnaire booklet took a maximum of 20 min to complete.

### Study measures

The *Hospital Anxiety and Depression Scale (HADS)* is a 14-item scale with two subscales of seven items measuring the presence and severity of anxiety and depression.<sup>23</sup> Scores >11 suggest clinically significant anxiety or depression.

The *Cancer Worry Scale Revised* is an eight-item scale that measures worry about the risk of developing cancer.<sup>24–27</sup> A higher score indicates greater worry.

The *Impact of Events Scale (IES)* is a 15-item scale measuring the frequency of intrusive and avoidant thoughts about a specific life event.<sup>28</sup> Respondents completed one scale for cancer and another for MRI. A higher score indicates higher distress levels; a score of >8.5 on either scale indicates clinically significant levels of distress.<sup>29</sup>

The *Spielberger State Anxiety Inventory-B (brief form)* is a six-item scale abbreviated from the original 20-item scale<sup>30</sup> and evaluates situational factors that may influence anxiety levels.<sup>31 32</sup> In this study it was used to measure state anxiety related to the MRI scan.

The *Health Questionnaire (HQ)* is a seven-item scale which was developed for use in a study investigating distress caused by attending routine breast screening.<sup>33</sup> Respondents indicate for each stress-sensitive behaviour whether, in the last week, it has been 'better than normal' (score 0), same as normal (score 1) or worse than normal (score 2).

The *Short Form-36 Health Survey V.2 (SF36-II)* is a 36-item generic measure of HRQoL<sup>34 35</sup> measuring eight dimensions of health. Scores are converted linearly to a 0–100 scale, with a higher score representing better functioning. Summary scores are calculated for physical health and mental health.

In *Perceived Risk*, participants rate their perceived risk of developing cancer compared with the average person's risk and express their lifetime risk of developing cancer as a percentage.

*Screening Satisfaction Questionnaire (SSQ)* is a series of Likert scales originally designed to assess the satisfaction of individuals undergoing breast mammography<sup>36</sup> and later adapted for MRI screening.<sup>22</sup> The higher the score, the lower the satisfaction.

In the *Acceptability of Screening*, participants were asked 'If you were offered an MRI scan next year, would you attend?' and 'would you encourage a family member to attend for an MRI screening scan?'

### Sample size and statistical analysis

SIGNIFY had 88 participants: 44 *TP53* pv carriers and 44 healthy population controls. This sample size was based on the expected cancer detection rates using WB-MRI screening in the two groups.<sup>12</sup>

If <75% of the items on any questionnaire were completed, the data were excluded. Where >75% of items were completed, a pro rata total score was calculated. The only exception was for the SF36-II, where data were excluded when <50% of the items of a subscale were completed, as recommended by the questionnaire developers.<sup>37</sup>

Descriptive statistics were calculated to summarise the characteristics of participants and the questionnaire data. Between-group differences at the various time-points were analysed using the Mann-Whitney U test, Fisher's exact probability test and the  $\chi^2$  test as appropriate; within-group changes over time were evaluated using the Wilcoxon signed-rank test and the McNemar test.

The effects of other variables such as previous cancer diagnosis and undergoing additional investigations post-MRI were analysed using the Mann-Whitney U test and the  $\chi^2$  test. Alpha was set at 0.05 (two-tailed).

Data were analysed using SPSS V.24.0.

## RESULTS

### Sample characteristics and response rate

As previously reported, 6 of 44 (14%) carriers were diagnosed with cancer during their involvement in the study.<sup>12</sup>

All 88 (100%) participants completed the baseline questionnaires. Overall, over 52 weeks, questionnaire compliance was 85.3% (510 of 598 questionnaires administered). No significant difference in questionnaire response rate was observed between carriers and controls ( $p=0.38$ ). Non-response was not associated with an adverse or clinically significant baseline score on a psychological scale (HADS,  $p=0.28$ ; IES,  $p=0.12$ ) or with a previous cancer diagnosis ( $p=0.65$ ).

The sociodemographic characteristics of participants are shown in table 1. There were 27 women and 17 men in each cohort. The mean ages of carriers and controls were 37.6 years and 38.3 years, respectively. Most participants were white (95% carriers, 91% controls), in professional or managerial positions (50% carriers, 82% controls), and married (63% carriers, 66% controls). The number of people in professional jobs was higher in controls ( $\chi^2=0.36$ ,  $p=0.02$ ), and the control group had more people with degrees and postgraduate qualifications ( $\chi^2=0.43$ ,  $p=0.005$ ).

### Hospital Anxiety and Depression Scale

The prevalence of clinically significant anxiety and depression (score  $\geq 10$ ) did not differ significantly between the groups at any time-point. Similarly, the mean scores of carriers and controls were similar throughout the study. At 12 weeks post-results, carriers reported more borderline and clinically significant anxiety combined (score  $\geq 8$ ) than controls ( $p=0.036$ ). The anxiety scores of carriers declined significantly from baseline to preresults ( $Z=-2.07$ ,  $p=0.04$ ; table 2).

In carriers, the prevalence of clinically significant or borderline anxiety and depression in those with a history of cancer did not differ at any time-point from those without such a history (table 3). Similarly, these two groups did not differ for anxiety and depression scores (table 3).

The prevalence of clinically significant or borderline anxiety and depression did not differ significantly at any time-point for

**Table 1** Sociodemographic characteristics of cohorts

	Carriers (n=44)	Controls (n=44)	
Sex			$\chi^2=0.00$ , $p=1.00$
Female	27 (61%)	27 (61%)	
Male	17 (39%)	17 (39%)	
Age			$t=-0.33$ , $p=0.75$
Mean	37.6	38.3	
Range	19–58	22–59	
Ethnicity			$\chi^2=1.38$ , $p=0.71$
White	42 (95%)	40 (91%)	
Asian/Asian British	1 (2%)	2 (5%)	
Chinese/Other	0	1 (2%)	
Mixed	1 (2%)	1 (2%)	
Education			$\chi^2=21.39$ , $p=\leq 0.005^*$
None	2 (5%)	0	
School to 16	9 (20%)	3 (7%)	
School to 18	9 (20%)	1 (2%)	
Technical	10 (23%)	5 (11%)	
Degree/postgraduate	14 (32%)*	34 (77%)*	
Missing	0	1 (2%)	
Employment			$\chi^2=2.05$ , $p=0.56$
Currently employed	36 (82%)	38 (86%)	
Not currently employed	6 (14%)	3 (7%)	
Retired	2 (5%)	2 (5%)	
Missing	0	1 (2%)	
Marital status			$\chi^2=0.72$ , $p=0.70$
Married	15 (63%)	29 (66%)	
Single	9 (38%)	14 (32%)	
Divorced	0	1 (2%)	
Missing	20	0	
Socioeconomic classification			$\chi^2=11.22$ , $p=0.04^*$
Professional/managerial	21 (48%)*	36 (82%)*	
Skilled manual/non-manual	15 (34%)	5 (11%)	
Partly skilled manual/unskilled	8 (18%)	3 (7%)	
Missing	0	0	

\*Significant difference between carriers and controls.

carriers requiring further investigations compared with those who did not (table 4).

### Cancer Worry Scale Revised

Carriers had significantly greater mean cancer worry scores than controls at baseline ( $U=499$ ,  $\leq p=0.0005$ ), at 26 weeks' follow-up ( $U=289$ ,  $\leq p=0.0005$ ) and at 52 weeks' follow-up ( $U=219$ ,  $\leq p=0.0005$ ). No significant changes over time were observed in carriers. In contrast, the mean cancer worry scores declined significantly in controls between baseline and 52 weeks' follow-up ( $Z=-2.06$ ,  $p=0.04$ ) (table 2).

Having a previous cancer diagnosis and having further investigations did not have a significant effect, at any time-point, in carriers.

### IES: thoughts about cancer

#### Intrusive thoughts about cancer

Compared with controls, carriers had more frequent intrusive thoughts at every time-point (preresults  $U=264$ ,  $p=\leq 0.0005$ ; 12 weeks' follow-up  $U=263$ ,  $p=\leq 0.0005$ ; 26 weeks' follow-up  $U=198$ ,  $p=\leq 0.0005$ ; and 52 weeks' follow-up  $U=192$ ,

Table 2 Descriptive statistics and summary of psychological outcomes

Scale	Study enrolment		At MRI appointment		Preresults		12 weeks after results		26 weeks after results		52 weeks after results		
	Scale range/ threshold	Carriers (n=44)	Controls (n=44)	Carriers (n=37)	Controls (n=37)	Carriers (n=36)	Controls (n=38)	Carriers (n=29)	Controls (n=38)	Carriers (n=33)	Controls (n=38)	Carriers (n=28)	Controls (n=34)
HADS Anxiety, mean (SD); n above threshold	0–1 0–7 8–10 >10	6.2 (3.9)* 28 10 6	4.9 (3.3) 36 5 3	– – – –	– – – –	5.3 (3.9)* 29 3 4	4.1 (3.1) 34 11 3†	5.8 (4.3) 19 5† 5†	4.1 (3.1) 34 11 3†	5.9 (4.1) 22 7 2	4.4 (2.9) 32 5 1	5.7 (4.8) 19 5 4	4.1 (3.2) 30 2 2
HADS Depression, mean (SD); n above threshold	0–21 0–7 8–10 >10	2.3 (2.5) 42 2 0	2.1 (1.9) 43 1 0	– – – –	– – – –	2.4 (2.8) 34 0 2	1.8 (2.3) 37 1 1	2.3 (3.3) 26 1 2	1.8 (2.3) 37 1 0	2.6 (2.8) 27 4 0	2.3 (2.8) 37 0 1	3.0 (3.8) 25 2 1	2.1 (2.3) 33 1 0
CWS-R, mean (SD)	8–32	14.4 (3.6)†	12.2 (1.7)*†	–	–	–	12.1 (1.9)	13.6 (4.4)	12.1 (1.9)	14.7 (4.2)†	11.9 (1.8)†	14.5 (4.3)†	11.9 (1.4)*†
IES: cancer intrusion	0–35 0–8 >8	– – –	– – –	– – –	– – –	11.4 (9.1)*† 15 21†	1.8 (3.1)† 35 3†	8.3 (9.1)*† 18 10†	1.8 (3.1)† 35 3†	11.0 (10.0)† 15 16†	1.7 (3.5)*† 36 2†	9.2 (8.2)† 14 13†	2.1 (3.8)† 32 2†
IES: cancer avoidance	0–40 0–8 >8	– – –	– – –	– – –	– – –	13.3 (10.5)† 13 23†	3.8 (5.9)*† 31 7*†	9.9 (9.0)† 12 16†	3.8 (5.9)*† 31 7*†	13.4 (11.7)† 12 19†	4.3 (6.7)† 31 7†	10.1 (9.4)† 12 15†	2.6 (4.6)*† 30 4†
IES: MRI	0–35 0–8 >8	– – –	– – –	– – –	– – –	– – –	0.5 (1.8) 37 1	1.7 (3.6) 26 2	0.5 (1.8) 37 1	3.1 (8.8)† 29 2	0.3 (1.4)† 38 0	1.2 (3.2)† 26 1	0.1 (0.3)† 34 0
IES: MRI avoidance	0–40 0–8 >8	– – –	– – –	– – –	– – –	– – –	2.8 (1.8) 35 3	2.8 (5.5) 24 4	2.8 (1.8) 35 3	4.1 (9.3)† 29 2	0.8 (1.4)† 35 3	1.8 (3.4) 26 1	1.0 (0.3) 31 3
SSAI, mean (SD)	6–24	–	–	7.2 (3.3)	7.3 (3.2)	–	–	–	–	–	–	–	–
Health Questionnaire, mean (SD)	0–14	7.0 (2.6)	6.8 (2.2)	–	–	8.1 (2.8)†	7.7 (2.1)	7.1 (2.5)	7.7 (2.1)	7.2 (2.4)	7.2 (2.2)	7.2 (2.6)	7.6 (1.5)
SF36-II physical component summary, mean (SD)	0–100	49.2 (6.1)†	52.1 (4.5)†	–	–	–	–	50.7 (8.5)	52.0 (5.5)	48.4 (8.2)†	51.7 (9.0)†	47.9 (9.8)†	51.7 (7.3)†
SF36-II mental component summary, mean (SD)	0–100	50.2 (8.3)†	54.0 (6.8)†	–	–	–	–	50.0 (10.2)	53.2 (9.9)	49.3 (10.0)	52.1 (9.5)	49.3 (10.0)	53.3 (8.7)
Risk Perception, mean (SD)	0–100	68.7† (24.9)	27.0† (17.8)	–	–	–	–	71.2† (24.4)	30.6† (16.4)	70.6† (25.5)	33.9† (18.7)	67.7† (27.0)	35.7† (19.4)

\*Significant difference in scores between time-points (same group) compared with baseline (first) measure.

†Significant difference in scores between groups.

CWS-R, Cancer Worry Scale Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Events Scale; SF36-II, Short Form-36 Health Survey V.2; SSAI, Spielberger State Anxiety Inventory.

**Table 3** Descriptive statistics and summary of psychological outcomes of *TP53* carriers with a previous cancer diagnosis vs with those who are unaffected

Scale	Scale range/threshold	Study enrolment				Preresults				12 weeks after results				26 weeks after results				52 weeks after results			
		Previous cancer (n=15)	Unaffected (n=29)	Previous cancer (n=14)	Unaffected (n=22)	Previous cancer (n=9)	Unaffected (n=20)	Previous cancer (n=12)	Unaffected (n=20)	Previous cancer (n=9)	Unaffected (n=20)	Previous cancer (n=9)	Unaffected (n=20)	Previous cancer (n=9)	Unaffected (n=20)	Previous cancer (n=9)	Unaffected (n=19)				
HADS Anxiety, mean (SD); n above threshold	0–21	6.3 (3.6)	6.1 (4.1)	5.3 (3.8)	5.3 (4.0)	4.9 (4.7)	6.3 (4.1)	5.6 (3.8)	6.1 (4.3)	5.7 (3.8)	5.7 (3.8)	6.1 (4.3)	5.7 (3.8)	5.7 (3.8)	5.7 (3.8)	5.7 (3.8)	5.7 (5.3)				
	0–7	10	19	11	18	6	13	8	14	7	7	14	7	12	7	12	12				
	8–10	4	5	1	2	2	3	3	4	1	4	3	4	4	1	4	4				
	>10	1	5	2	2	1	4	1	1	1	1	1	1	1	1	3	3				
HADS Depression mean (SD); n above threshold	0–21	2.1 (2.0)	2.4 (2.8)	2.3 (2.9)	2.5 (2.8)	1.7 (2.7)	2.6 (3.6)	2.8 (3.2)	2.4 (2.6)	4.1 (3.9)	4.1 (3.9)	2.4 (2.6)	4.1 (3.9)	2.5 (3.8)	4.1 (3.9)	2.5 (3.8)	2.5 (3.8)				
	0–7	15	27	13	21	8	18	10	18	7	18	10	18	18	7	18	18				
	8–10	0	2	0	0	1	0	2	2	2	2	2	2	2	2	0	0				
	>10	0	0	1	1	0	2	0	0	0	0	0	0	0	0	1	1				
CWS-R, mean (SD)	8–32	14.2 (2.1)	14.5 (4.1)	13.1 (2.6)	13.8 (5.1)	13.4 (2.2)	15.4 (4.9)	13.0 (2.8)	15.2 (4.7)	14.2 (2.1)	14.2 (2.1)	13.0 (2.8)	15.2 (4.7)	14.5 (4.1)	14.2 (2.1)	14.5 (4.1)	14.5 (4.1)				
IES: cancer intrusion	0–35	–	–	9.6 (6.7)	12.6 (10.2)*	8.6 (9.0)	8.1 (9.4)*	8.2 (8.5)	12.6 (10.7)	8.1 (8.4)	8.1 (8.4)	8.2 (8.5)	12.6 (10.7)	9.7 (8.3)	8.1 (8.4)	9.7 (8.3)	9.7 (8.3)				
	0–8	–	–	5	9	5	13	6	8	4	4	6	8	10	4	10	10				
	>8	–	–	9	13	4	6	5	12	4	4	5	12	9	4	9	9				
IES: cancer avoidance	0–40	–	–	12.5 (8.6)	13.8 (11.7)	9.0 (7.8)	10.4 (9.7)	11.5 (11.6)	14.4 (10.0)	7.8 (7.2)	7.8 (7.2)	11.5 (11.6)	14.4 (10.0)	11.1 (10.2)	7.8 (7.2)	11.1 (10.2)	11.1 (10.2)				
	0–8	–	–	5	7	3	8	6	6	3	3	6	6	8	3	8	8				
	>8	–	–	9	15	6	11	5	14	5	5	5	14	11	5	11	11				

\* Significant difference in mean scores between time-points (same group).  
CWS-R, Cancer Worry Scale Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Events Scale.



**Table 4** Descriptive statistics and summary of psychological outcomes of TP53 carriers requiring further investigations vs with those not requiring further investigations

Scale	Scale range/threshold	Study enrolment			12 weeks after results*			+26 weeks after results*			52 weeks after results*		
		No investigations (n=28)	Further investigations (n=16)		No investigations (n=20)	Further investigations (n=9)		No investigations (n=18)	Further investigations (n=13)		No investigations (n=18)	Further investigations (n=10)	
HADS Anxiety, mean (SD); n above threshold	0–21	6.0 (4.4)	6.6 (3.1)		5.2 (4.5)	7.2 (3.5)		5.6 (3.4)	6.3 (5.0)		5.6 (5.0)	5.8 (4.8)	
	0–7	18	11		14	5		13	9		13	6	
	8–10	5	4		3	2		4	3		2	3	
	>10	5	1		3	2		1	1		3	1	
HADS Depression mean (SD); n above threshold	0–21	1.8 (1.9)	3.1 (3.1)		1.9 (3.1)	3.0 (3.8)		2.1 (2.4)	3.2 (3.2)		2.7 (3.0)	3.6 (5.1)	
	0–7	28	14		18	8		16	11		16	9	
	8–10	0	0		1	0		2	2		2	0	
	>10	0	2		1	1		0	0		0	1	
CWS-R, mean (SD)	8–32	13.7 (2.1)	15.6 (5.1)		13.2 (2.4)	14.6 (7.1)		14.4 (3.6)	15.1 (5.3)		14.0 (3.4)	15.4 (5.7)	
IES: cancer intrusion	0–35	–	–		8.6 (8.4)	7.4 (11.0)		10.3 (9.7)	11.9 (10.8)		8.2 (6.6)	10.9 (10.6)	
	0–8	–	–		11	7		9	6		9	5	
	>8	–	–		8	2		9	7		8	5	
IES: cancer avoidance	0–40	–	–		9.1 (7.9)	11.6 (11.4)		11.0 (11.6)	16.6 (11.6)		8.2 (7.6)	13.3 (11.6)	
	0–8	–	–		8	4		9	3		9	3	
	>8	–	–		11	5		9	10		8	7	

\*n=number of questionnaires returned at each time-point. Participants receiving a cancer diagnosis did not complete questionnaires beyond the time of diagnosis.

CWS-R, Cancer Worry Scale Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Events Scale.

$p \leq 0.0005$ ). They also reported significantly more clinically significant intrusive thoughts (score  $>9$ ) than controls at all time-points: at preresults ( $p \leq 0.0005$ ), at 12 weeks' follow-up ( $p = 0.01$ ), at 26 weeks' follow-up ( $p \leq 0.0005$ ) and at 52 weeks' follow-up ( $p \leq 0.0005$ ; [table 2](#)).

Intrusion scores declined significantly in carriers between preresults and 12 weeks' follow-up ( $Z = -2.15$ ,  $p = 0.032$ ). Scores also declined in controls between preresults and 26 weeks' follow-up ( $Z = -2.68$ ,  $p = 0.07$ ).

For carriers without a previous cancer diagnosis ([table 3](#)), intrusion scores fell between preresults and 12 weeks' follow-up (12.6 vs 8.1;  $Z = -2.63$ ,  $p = 0.009$ ).

No significant differences in intrusion scores were found at any time-point for carriers requiring further investigations compared with those who did not ([table 4](#)).

### Avoidance of thoughts about cancer

Carriers reported significantly more clinically significant avoidance than controls at all time-points: preresults ( $p = 0.036$ ), 12 weeks' follow-up ( $p = 0.002$ ), 26 weeks' follow-up ( $p = 0.01$ ) and 52 weeks' follow-up ( $p \leq 0.0005$ ).

Compared with controls, carriers had more frequent avoidance at every time-point (preresults  $U = 423$ ,  $p = 0.005$ ; 12 weeks' follow-up  $U = 304$ ,  $p = 0.002$ ; 26 weeks' follow-up  $U = 296$ ,  $p \leq 0.0005$ ; and 52 weeks' follow-up  $U = 252$ ,  $p = 0.01$ ).

In the control group, compared with preresults, the prevalence of clinically significant avoidance fell at 12 weeks' follow-up (McNemar:  $p = 0.04$ ) and at 52 weeks' follow-up (McNemar:  $p = 0.01$ ).

Avoidance scores in controls declined significantly between preresults and 12 weeks' follow-up ( $Z = -2.73$ ,  $p = 0.006$ ) and preresults and 52 weeks' follow-up ( $Z = -3.38$ ,  $p = 0.001$ ).

No significant differences in avoidance scores were found at any time-point for carriers requiring further investigations compared with those who did not.

### IES: thoughts about MRI

#### Intrusion of thoughts about MRI

The intrusion scores of carriers were significantly higher than those of controls at 26 weeks ( $U = 330$ ,  $p = 0.05$ ) and 52 weeks ( $U = 284$ ,  $p = 0.02$ ) postresults.

There were no significant differences in the number of participants over the threshold of clinically significant levels of intrusive thoughts about MRI between carriers and controls, or within each group, at any time-point ([table 2](#)).

Intrusion scores declined significantly in controls between 12 and 52 weeks postresults ( $Z = -2.12$ ,  $p = 0.03$ ). However, all mean scores were very low and overall represented low levels of avoidant thoughts about the MRI scan.

Mean intrusion scores did not vary significantly across time-points for mutation carriers.

### Avoidance of thoughts about MRI

There were no significant differences in clinically significant avoidance between carriers or controls, or within each group, at any time-point ([table 2](#)). The mean avoidance score of carriers was significantly higher than that of controls 26 weeks postresults ( $U = 301$ ,  $p = 0.05$ ). Mean avoidance scores did not vary significantly over time within carrier or control groups. All mean scores were very low.

### Spielberger State Anxiety Inventory

No significant difference at the time of MRI was detected in state anxiety between carriers and controls and the mean scores were overall low on the scale.

### Health Questionnaire

Carriers had significantly higher mean scores for stress-sensitive behaviours preresults compared with controls at 12 weeks ( $U = 472$ ,  $p = 0.02$ ) but not at other time-points. Scores did not vary significantly over time within either group.

### SF36-II questionnaire

#### Physical function

Carriers had poorer physical functioning than controls at baseline and at 26 and 52 weeks postresults ( $U = 645$ ,  $p = 0.007$ ;  $U = 398$ ,  $p = 0.02$ ;  $U = 318$ ,  $p = 0.03$ , respectively). However, the effect size was small and the mean values were close to the standardised mean of 50 across both groups and at all time-points.

No significant differences in mean scores were detected for physical functioning scores between baseline and any other time-point in either carriers or controls.

#### Mental function

Carriers had poorer mental functioning than controls at baseline ( $U = 723$ ,  $p = 0.03$ ). However, the effect size was small and the mean values were close to the standardised mean of 50 across both groups and at all time-points.

No significant differences in mean scores were detected for mental functioning scores between baseline and any other time-point in either carriers or controls.

### Risk Perceptions

Carriers estimated their risk of developing cancer as higher than controls at every time-point (baseline  $U = 183$ ,  $p < 0.0005$ ; 12 weeks  $U = 116$ ,  $p < 0.0005$ ; 26 weeks  $U = 165$ ,  $p < 0.0005$ ; 52 weeks  $U = 147$ ,  $p < 0.0005$ ) ([table 2](#)).

The majority of carriers classified their risk as 'moderately or strongly increased' ([table 5](#)) when compared with the general population risk, with 54%–58% correctly perceiving their risk as strongly increased. Of the controls, 64%–73% perceived their risk to be 'the same' as the general population.

**Table 5** Participants' classification of their risk of cancer when compared with the general population risk

	Baseline		12 weeks after results		26 weeks after results		52 weeks after results	
	Carriers (n=44)	Controls (n=42)	Carriers (n=28)	Controls (n=38)	Carriers (n=31)	Controls (n=39)	Carriers (n=26)	Controls (n=33)
Lower	0	11 (26%)	0	7 (18%)	0	10 (26%)	0	6 (18%)
The same	0	28 (67%)	1 (4%)	27 (71%)	1 (3%)	25 (64%)	2 (8%)	21 (64%)
Slightly increased	7 (16%)	3 (7%)	3 (11%)	3 (8%)	6 (19%)	4 (10%)	5 (19%)	5 (15%)
Moderately increased	13 (30%)	0	9 (32%)	1 (3%)	6 (19%)	0	4 (15%)	1 (3%)
Strongly increased	24 (55%)	0	15 (54%)	0	18 (58%)	0	15 (58%)	0

**Table 6** Participants' mean screening satisfaction scores

	Convenience and access		Staff interpersonal skills		Information transfer		Physical surroundings*		Perceived technical competence		General satisfaction	
	Carrier (n=37)	Control (n=37)	Carrier (n=37)	Control (n=37)	Carrier (n=37)	Control (n=37)	Carrier (n=37)	Control (n=37)	Carrier (n=37)	Control (n=37)	Carrier (n=37)	Control (n=37)
Mean (SD)	7.5 (2.8)	6.9 (2.3)	4.5 (1.5)	5.0 (1.5)	6.2 (2.3)	6.3 (2.0)	8.4 (3.0)	10.8 (3.5)	4.8 (1.6)	5.2 (1.4)	6.8 (2.7)	7.3 (2.3)
Possible range	4–20		4–20		4–20		5–25		4–20		5–25	

\*Significant difference in mean scores between groups.

### Screening Satisfaction

Carriers reported higher satisfaction scores with the physical surroundings of the MRI environment than controls ( $U=316$ ,  $p=0.03$ ; table 6).

### Acceptability of Screening

Ninety-eight per cent of carriers and 77% of controls agreed that they would attend an offered MRI scan the following year at every time-point (12, 26 and 52 weeks postresults;  $p=0.015$ ).

Eighty-six per cent of carriers and 86% of controls reported that they would encourage a family member to attend for MRI screening at every time-point.

### DISCUSSION

This is the first study to evaluate the psychosocial impact of WB-MRI in a cohort of *TP53* pv carriers compared with a matched general population control group. Overall there were minimal adverse psychological outcomes among study participants; while carriers reported higher levels of cancer worry and depression, this was not negatively impacted by the use of WB-MRI screening.

Reassuringly, there were no statistically significant differences in the prevalence of clinically significant anxiety or depression between carriers and controls at any time-point (when using a HADS of  $>10$ ). When a more stringent cut-off of 8 or more was used, the only difference between groups was at 12 weeks postresults, when carriers reported more borderline and clinically significant anxiety (34%) than controls (11%). When compared with normative data for the HADS score from a study of a large sample of general practice registrants in North West England,<sup>38</sup> the prevalence of clinically significant anxiety and depression in carriers was not high. The HADS mean scores in carriers are also similar to those of other genetically high-risk populations.<sup>39 40</sup>

McBride *et al*<sup>17</sup> reported anxiety scores in their cohort of LFS pv carriers to be highest at baseline, with a significant reduction 2 weeks post-MRI. Similarly, we found that the highest values in both cohorts were recorded at baseline for anxiety on the HADS and IES scales. McBride *et al*<sup>17</sup> suggest this could indicate a temporary increase in anxiety related to the anticipation of the MRI. Some of the difference may be related to anxiety about what the MRI might find: in the current study, there were no significant differences between groups when measuring MRI-specific anxiety. Falls in other measures over time support the concept that distress reduces after results are available. Twelve weeks after receipt of MRI results, IES values assessing intrusive thoughts about cancer were significantly lower in carriers compared with prerresults. A significant reduction in IES scores was seen at 26 weeks in controls. Scores of  $\geq 8$  (representing clinically significant levels of avoidant thoughts about cancer) also became fewer with time in controls at 12 weeks after the MRI results. The hypothesis regarding concern about MRI findings is supported by our finding of higher levels of stress-related

behaviours (measured on the HQ) in carriers compared with controls immediately before the MRI results. This is further supported by the results of the MARIBS study, which reported high levels of baseline psychological morbidity that reduced post-MRI breast screening.<sup>22</sup>

A small proportion of participants (cases and controls) had ongoing distress after results were provided. At 12 weeks postresults, 7% of carriers (3% of controls) had clinically significant levels of intrusive thoughts about the MRI, and 14% of carriers (8% of controls) had clinically significant levels of avoidant thoughts. There were no significant changes in the numbers of individuals affected by week 52, as numbers were small. In the general population, psychological reactions to MRI vary and a significant number of people have anxiety reactions ranging from anticipatory anxiety to a full-blown panic attack. Interventions to minimise and predict such symptoms have been documented.<sup>41</sup> Although 98% of carriers indicated that they would return for a further scan the following year, we recommend that the minority of carriers who suffer from significant MRI-related distress (be it pre-MRI, during MRI or post-MRI scan) should be offered evidence-based help in coping with future MRIs.

As expected, mean cancer-related worry scores were high in carriers and significantly higher than in controls. It is well documented that living with a *TP53* pv is a psychosocial burden for patients.<sup>17 27 42</sup> It is also known that living in a family with a *TP53* pv has an adverse psychosocial impact regardless of pv status.<sup>27</sup> It was also, therefore, a strength of this study that controls were sought outside of these families.

It could be hypothesised that carriers with a previous cancer diagnosis may have a worse psychosocial experience when undergoing cancer screening. However, a previous cancer diagnosis was not associated with any worse psychosocial outcomes. Indeed, carriers with a previous cancer had lower mean scores for anxiety at 6 and 12 months post-WB-MRI compared with unaffected carriers. This needs further exploration in a larger series, but may suggest a degree of post-traumatic growth among the participants with previous cancer diagnoses.<sup>43</sup> This is a growing area of interest in cancer survivors.

Sensitive measures and interventions to manage fear of cancer recurrence are being evaluated.<sup>44 45</sup> High levels of fear of recurrence are usually associated with psychological morbidity and poor HRQoL, as seen in carriers living at risk of multiple cancers.<sup>45</sup> Therefore strategies to increase resilience and reduce cancer fear could be potentially very beneficial to improve psychosocial well-being in this group.

Importantly, no clinically significant differences were detected between carriers requiring additional investigations for an abnormality found on MRI and those requiring no additional investigations, either in the short or medium term. In McBride *et al*'s study, qualitative interviews found that, despite an initial high level of faith in the efficacy of WB-MRI, a large proportion of participants reported the MRI to be burdensome, particularly in



those requiring additional investigations.<sup>17</sup> However, this study was limited by its small numbers (nine participants were interviewed 6 months after the MRI and data collection is ongoing). We found no evidence to support this finding, with no differences reported in either HRQoL or psychosocial measures at 12, 26 or 52 weeks post initial results. It is reasonable to assume that by 12 weeks any further investigations would have been completed and participants would have known the outcome. Therefore any short-term impact on distress levels during the period of uncertainty of a diagnosis may have been missed with this study design. Overall, our data indicate that additional investigations triggered by the MRI did not add a longer-term psychosocial burden for carriers.

In terms of general HRQoL, significant differences were detected in SF36 scores between carriers and controls in both physical and mental functioning. However, this did not change over time, and all scores were similar to previously published norms.<sup>34</sup> Carriers had a slightly poorer overall HRQoL, but undergoing MRI screening had no impact on HRQoL.

Only 55%–57% of carriers correctly estimated their risk of cancer at each time-point as ‘strongly’ increased when compared with the general population risk. Almost half of pv carriers underestimated their lifetime risk of cancer, 15%–20% very substantially. This may be a coping strategy rather than a shortcoming regarding information given or understood. Either way, it highlights the need for ongoing easy-to-access information and support. McBride *et al*<sup>17</sup> found that undergoing screening and having contact with a clinician were emotionally helpful.<sup>17</sup> Therefore, in addition to the utility of WB-MRI, future research should evaluate types of support for carriers undergoing screening.

The SSQ findings demonstrate very high satisfaction levels with all aspects of screening in all participants. Schmidt *et al*'s<sup>19</sup> evaluation of WB-MRI screening in the general population found similar results. Almost all carriers (98%) stated that they would attend for a repeat scan in a year's time, demonstrating a very high level of acceptability of WB-MRI screening. Significantly fewer controls (77%) stated they would attend for a repeat scan, perhaps because their risk of cancer was significantly lower. In both groups, 86% would recommend a relative attends for WB-MRI screening.

### Strengths and limitations

Compliance with questionnaire completion was very good, and there was no association between an adverse baseline score and subsequent non-response. Of note, just three participants completed only the baseline questionnaire.

A unique strength of this study was the use of a control group. This, together with the longitudinal design, allowed comparisons between and within cohorts over time.

The two groups were well matched for a range of sociodemographic variables, including employment, marital status, ethnicity and age. However, controls had a significantly higher level of education and higher socioeconomic status than the carriers. Given that higher educational attainment and socioeconomic status have been shown to protect against both depression and anxiety, the comparability of the two groups in terms of observed anxiety and depression is additionally reassuring.<sup>46</sup>

### CONCLUSION

WB-MRI screening is very acceptable to carriers and is associated with minimal medium-term adverse psychosocial outcomes. The presence of a *TP53* pv is well known to cause adverse

psychosocial outcomes for some, but there is no evidence that WB-MRI screening exacerbated cancer worry or depression. There was evidence of a transient increase in anxiety pre-MRI, but this might have been due to anticipation of what screening might detect, rather than undergoing MRI. The study population had a high level of satisfaction with the WB-MRI screening process.

Reassuringly there was no adverse psychosocial impact observed in the carriers requiring additional investigations for an abnormality detected at MRI, and a previous cancer diagnosis may predict a better psychosocial outcome.

Some carriers seriously underestimate their risk of cancer, raising the question of maladaptive coping strategies. We recommend easy access to a clinician for all mutation carriers to help them cope with cancer-related concerns, including intrusive cancer-related thoughts and images, and to respond appropriately to clinically significant depression and/or anxiety should it occur. Any carriers who suffer from procedural anxiety related to screening should be offered help from a clinician conversant with evidence-based anxiety management techniques.

### Author affiliations

<sup>1</sup>Oncogenetics Team, The Royal Marsden NHS Foundation Trust, London, UK

<sup>2</sup>Oncogenetics Team, The Institute of Cancer Research, London, UK

<sup>3</sup>Centre for Cancer Research & Department of General Practice, University of Melbourne, Melbourne, Victoria, Australia

<sup>4</sup>Medical Oncology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

<sup>5</sup>Clinical Genetics, Manchester University NHS Foundation Trust, Manchester, UK

<sup>6</sup>South West Thames Regional Genetics Service, St Georges NHS Foundation Trust, London, UK

<sup>7</sup>St Luke's Cancer Centre, Royal Surrey County Hospital, Guildford, UK

<sup>8</sup>Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, UK

<sup>9</sup>Clinical Genetics, Wessex Clinical Genetics Service, Southampton, UK

<sup>10</sup>Clinical Genetics, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

<sup>11</sup>Clinical Genetics, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

<sup>12</sup>Department of Clinical Genetics, Sheffield Children's Hospital, Sheffield, UK

<sup>13</sup>Clinical Genetics, University Hospitals of Leicester NHS Trust, Leicester, UK

<sup>14</sup>Clinical Genetics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

<sup>15</sup>North West Thames Regional Genetics Service (Kennedy-Galton Centre), London North West University Healthcare NHS Trust, Harrow, UK

<sup>16</sup>Cancer Sciences, University of Southampton Faculty of Medicine, Southampton, UK

<sup>17</sup>Department of Diagnostic Radiology, The Royal Marsden NHS Foundation Trust, London, UK

<sup>18</sup>Radiotherapy and Imaging, The Institute of Cancer Research, London, UK

<sup>19</sup>Formerly at the Familial Cancer Centre, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

<sup>20</sup>Department of Radiology, University of Cambridge, Cambridge, UK

<sup>21</sup>Cancer Genetics Service, Mater Hospital School, Dublin, Ireland

<sup>22</sup>Radiology, Manchester Royal Infirmary, Manchester, UK

<sup>23</sup>Radiology, St Mary's Hospital, Manchester, UK

<sup>24</sup>Postgraduate Medical Studies, University of Hull, Hull, UK

**Twitter** Sibel Saya @sibel\_saya

**Acknowledgements** We thank all the participants and families who took part in this research, as well as our funders who made this research possible. Permission to use the Impact of Events Scale for this research was granted by Dr Mardi J Horowitz and colleagues; the IES is governed by official copyright laws and was copyright 1979.

**Contributors** LeW, EKB, EB, SiS, DGE and RAE contributed to the concept and study design. EKB, LeW and RAE wrote the manuscript. EKB, SiS, EP, AC, JP, JR, ST and DGE collected the data and analysed or interpreted the data. JR, NT, ST, HH, JP, SB, CM, ADi, ADo, JAC, JB, VW, LL, LiW, DME, MOL, SSh, FG, DG, BR, RWW, MK, SuS and DGE recruited patients and/or performed the clinical evaluation of patients. All authors revised and approved the final version. LeW and EKB are responsible for the overall content.

**Funding** This work was supported by a grant from The Annabel Evans Memorial Fund to The Royal Marsden Cancer Charity. This study represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of

Cancer Research, London. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. This study was supported by the Clinical Research Facility at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, together with support to the CRUK Cancer Imaging Centre (C1060/A16464). DGE is supported by an NIHR research grant to the Biomedical Research Centre Manchester (IS-BRC-1215-20007). FG receives funding from the NIHR as a senior investigator.

**Competing interests** RAE: (1) GU-ASCO meeting in San Francisco, January 2016: honorarium as speaker, \$500; (2) Royal Marsden NHS Foundation Trust talk (Title: Genetics and Prostate Cancer), November 2017: £1100 support from Janssen; and (3) University of Chicago invited talk, May 2018: honorarium as speaker, \$1000.

**Patient consent for publication** Not required.

**Ethics approval** The SIGNIFY study was approved by the Health Research Authority NRES Committee London-Brent (12/LO/0781).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Elizabeth K Bancroft <http://orcid.org/0000-0002-5482-5660>

Sibel Saya <http://orcid.org/0000-0002-4796-6852>

Diana M Eccles <http://orcid.org/0000-0002-9935-3169>

D Gareth Evans <http://orcid.org/0000-0002-8482-5784>

#### REFERENCES

- Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. *Hum Mutat* 2003;21:313–20.
- Li FP, Fraumeni JF. Soft-Tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? *Ann Intern Med* 1969;71:747–52.
- Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T. 2009 version of the Chompret criteria for Li Fraumeni syndrome. *J Clin Oncol* 2009;27:e108–9.
- Bougeard G, Renaux-Petel M, Flaman J-M, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugières L, Caron O, Benusiglio PR, Bressac-de Paillerets B, Bonadona V, Bonaïti-Pellié C, Tinat J, Baert-Desurmont S, Frébourg T. Revisiting Li-Fraumeni Syndrome from TP53 Mutation Carriers. *J Clin Oncol* 2015;33:2345–52.
- Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. *J Clin Oncol* 2009;27:1250–6.
- Nichols KE, Malkin D, Garber JE, Fraumeni JF, Li FP. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. *Cancer Epidemiol Biomarkers Prev* 2001;10:83–7.
- Mai PL, Best AF, Peters JA, DeCastro RM, Khincha PP, Loud JT, Bremer RC, Rosenberg PS, Savage SA. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. *Cancer* 2016;122:3673–81.
- Amadou A, Waddington Achatz MI, Hainaut P. Revisiting tumor patterns and penetrance in germline TP53 mutation carriers: temporal phases of Li-Fraumeni syndrome. *Curr Opin Oncol* 2018;30:23–9.
- Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, Gallinger B, Naumer A, Kohlmann W, Novokmet A, Tabori U, Tijerim M, Greer M-LC, Finlay JL, Schiffman JD, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. *Lancet Oncol* 2016;17:1295–305.
- Kratz CP, Achatz MI, Brugières L, Frébourg T, Garber JE, Greer M-LC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtlar KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. *Clin Cancer Res* 2017;23:e38–45.
- National Institute for Health and Clinical Excellence. Clinical guideline 164: familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2017. Available: <https://www.nice.org.uk/>
- Saya S, Killick E, Thomas S, Taylor N, Bancroft EK, Rothwell J, Benafif S, Dias A, Mikropoulos C, Pope J, Chamberlain A, Gunapala R, Izatt L, Side L, Walker L, Tomkins S, Cook J, Barwell J, Wiles V, Limb L, Eccles D, Leach MO, Shanley S, Gilbert FJ, Hanson H, Gallagher D, Rajashanker B, Whitehouse RW, Koh D-M, Sohaib SA, Evans DG, Eeles RA, SIGNIFY Study Steering Committee. Baseline results from the UK signify study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. *Fam Cancer* 2017;16:433–40.
- Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. *Lancet Oncol* 2011;12:559–67.
- Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germline TP53 mutations. *Curr Opin Oncol* 2015;27:332–7.
- Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak R, Balieiro da Costa A, Santiago KM, Garber J, O'Neill AF, Eeles RA, Evans DG, Bleiker E, Sonke GS, Ruijs M, Loo C, Schiffman J, Naumer A, Kohlmann W, Strong LC, Bojadzieva J, Malkin D, Rednam SP, Stoffel EM, Koeppel E, Weitzel JN, Slavin TP, Nehoray B, Robson M, Walsh M, Manelli L, Villani A, Thomas DM, Savage SA. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging. *JAMA Oncology* 2017;3:1634–9.
- McBride KA, Ballinger ML, Killick E, Kirk J, Tattersall MHN, Eeles RA, Thomas DM, Mitchell G. Li-Fraumeni syndrome: cancer risk assessment and clinical management. *Nat Rev Clin Oncol* 2014;11:260–71.
- McBride KA, Ballinger ML, Schlub TE, Young M-A, Tattersall MHN, Kirk J, Eeles R, Killick E, Walker LG, Shanley S, Thomas DM, Mitchell G. Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? *Fam Cancer* 2017;16:423–32.
- Cancer Genetics Group. UK cancer genetics groups consensus meeting, 2018. Available: [www.ukcgg.org/information-education/ukcgg-consensus-meetings/](http://www.ukcgg.org/information-education/ukcgg-consensus-meetings/)
- Schmidt CO, Sierocinski E, Hegenscheid K, Baumeister SE, Grabe HJ, Völzke H. Impact of whole-body MRI in a general population study. *Eur J Epidemiol* 2016;31:31–9.
- Schmidt CO, Hegenscheid K, Erdmann P, Kohlmann T, Langanke M, Völzke H, Puls R, Assel H, Biffar R, Grabe HJ. Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study. *Eur Radiol* 2013;23:1343–51.
- Leach MO, Boggis CRM, Dixon AK, Easton DF, Eeles RA, Evans DGR, Gilbert FJ, Griebisch I, Hoff RJC, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RML, MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) [Erratum in: *Lancet*. 2005 May 28-Jun 3;365(9474):1848]. *Lancet* 2005;365:1769–78.
- Hutton J, Walker LG, Gilbert FJ, Evans DG, Eeles R, Kwan-Lim GE, Thompson D, Pointon LJ, Sharp DM, Leach MO. UK Study Group for MRI screening in women at high risk study. psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS study. *Br J Cancer* 2011;104:578–86.
- Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–70.
- Lerman C, Trock B, Rimer BK, Boyce A, Jepsen C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. *Ann Intern Med* 1991;114:657–61.
- Watson M, Lloyd S, Davidson J, Meyer L, Eeles R, Ebbs S, Murday V. The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. *Br J Cancer* 1999;79:868–74.
- Douma KFL, Aaronson NK, Vasen HFA, Gerritsma MA, Gundy CM, Janssen EPA, Vriends AHJT, Cats A, Verhoef S, Bleiker EMA. Psychological distress and use of psychosocial support in familial adenomatous polyposis. *Psychooncology* 2010;19:289–98.
- Lammens CRM, Aaronson NK, Wagner A, Sijmons RH, Ausems MGEM, Vriends AHJT, Ruijs MWG, van Os TAM, Spruijt L, Gómez García EB, Kluijff I, Nagtegaal T, Verhoef S, Bleiker EMA. Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. *J Clin Oncol* 2010;28:3008–14.
- Horowitz M, Wilner N, Alvarez W. Impact of event scale: a measure of subjective stress. *Psychosom Med* 1979;41:209–18.
- Horowitz M. Stress response syndromes and their treatment. In: Goldberger L, Breznitz S, eds. *Handbook of stress: theoretical and clinical aspects*. New York: Free Press, 1982: 711–32.
- Spielberger C, Gorsuch R, Lushene R. *Manual for the State-Trait anxiety*. California: Consulting Psychologists Press, 1970.
- Marteau TM, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). *Br J Clin Psychol* 1992;31:301–6.
- Spielberger CD, Gorsuch RL, Lushene RD. *Manual for the State-Trait anxiety inventory – form Y*. Palo Alto, CA: Consulting Psychologists Press, 1983.
- Walker LG, Cordiner CM, Gilbert FJ, Needham G, Deans HE, Affleck IR, Hood DB, Mathieson D, Ah-See AK, Eremin O. How distressing is attendance for routine breast screening? *Psychooncology* 1994;3:299–304.
- Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. *Journal of Epidemiology & Community Health* 1999;53:46–50.
- Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30.

- 36 Cockburn J, Hill D, Irwig L, De Luise T, Turnbull D, Schofield P. Development and validation of an instrument to measure satisfaction of participants at breast screening programmes. *European Journal of Cancer and Clinical Oncology* 1991;27:827–31.
- 37 Maruish ME, DeRosa MA. *A guide to the integration of certified short form survey scoring and data quality evaluation capabilities*. QualityMetric Incorporated: Lincoln, RI, 2009.
- 38 Breeman S, Cotton S, Fielding S, Jones GT. Normative data for the hospital anxiety and depression scale. *Qual Life Res* 2015;24:391–8.
- 39 Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS. IMPACT study Steering Committee; impact Collaborators, Eeles RA, Aaronson NK. psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. *BJU Int* 2018.
- 40 Brain KE, Lifford KJ, Fraser L, Rosenthal AN, Rogers MT, Lancaster D, Phelps C, Watson EK, Clements A, Menon U. Psychological outcomes of familial ovarian cancer screening: no evidence of long-term harm. *Gynecol Oncol* 2012;127:556–63.
- 41 Anderson and Walker. Psychological aspects of MRI. In: Warren R, Coulthard A, eds. *Breast MRI in practice*. London: Martin Dunitz, 2002.
- 42 Peterson SK, Pentz RD, Marani SK, Ward PA, Blanco AM, LaRue D, Vogel K, Solomon T, Strong LC. Psychological functioning in persons considering genetic counseling and testing for Li-Fraumeni syndrome. *Psychooncology* 2008;17:783–9.
- 43 Lelorain S, Tessier P, Florin A, Bonnaud-Antignac A. Posttraumatic growth in long term breast cancer survivors: relation to coping, social support and cognitive processing. *J Health Psychol* 2012;17:627–39.
- 44 Butow PN, Turner J, Gilchrist J, Sharpe L, Smith AB, Fardell JE, Tesson S, O'Connell R, Girgis A, GebSKI VJ, Asher R, Mihalopoulos C, Bell ML, Zola KG, Beith J, Thewes B. Randomized trial of ConquerFear: a novel, theoretically based psychosocial intervention for fear of cancer recurrence. *J Clin Oncol* 2017;35:4066–77.
- 45 Fardell JE, Jones G, Smith AB, Lebel S, Thewes B, Costa D, Tiller K, Simard S, Feldstain A, Beattie S, McCallum M, Butow P, Conquer Fear authorship group. Exploring the screening capacity of the fear of cancer recurrence Inventory-Short form for clinical levels of fear of cancer recurrence. *Psychooncology* 2018;27:492–9.
- 46 Bjelland I, Krokstad S, Mykletun A, Dahl AA, Tell GS, Tambs K. Does a higher educational level protect against anxiety and depression? The HUNT study. *Soc Sci Med* 2008;66:1334–45.